Introduction
============

Celebrity endorsements of healthcare products and behaviours are ubiquitous. We studied the effect of a major announcement by actress Angelina Jolie, who in a 2013 *New York Times* editorial urged women to consider BRCA1/2 genetic testing and announced that she had undergone preventive mastectomy.[@ref1] The editorial is one of the most viewed health related articles in the social media age.[@ref2] [@ref3] To date, analyses of the editorial's effects have been limited to showing greater testing or referrals in small and specific subpopulations.[@ref4] [@ref5] Using data from a large commercially insured US population, we analysed rates of BRCA testing and mastectomy before and after Jolie's editorial.

Methods
=======

Data
----

Our study included women aged 18-64 years in the United States who were continuously enrolled in commercial insurance during 2012-13. Data came from the Truven MarketScan Analytics Commercial Claims and Encounters Database, which comprises de-identified health insurance claims for inpatient care, outpatient care, and prescription drugs for more than 50 million people covered by self insured employers and health plans. Details of this database have been published elsewhere.[@ref6]

Analysis
--------

We identified BRCA gene testing according to Current Procedural Terminology codes 81211-81217 in outpatient claims.[@ref5] We estimated changes in BRCA testing after the editorial by using an individual level difference-in-difference model that compared the change in probability of BRCA testing in the 15 business days before versus the 15 business days after 14 May with the change in the same period in 2012 (to account for potential seasonal trends). We selected this relatively narrow time window to attenuate concern that factors other than Jolie's editorial would confound our estimates. In a sensitivity analysis, however, we extended the time window to 30 days. Individual covariates included patient's age (18-25, 26-35, 36-45, 46-55, and 56-64 years), US Census region of residence (Northeast, North Central, South, West, unknown), and health plan type (preferred provider organisation (PPO), health maintenance organisation, consumer directed health plan, or other). Monthly BRCA testing rates in 2013, adjusted for number of days in the month, were reported to examine longer term trends. We estimated short term changes in spending on BRCA testing nationally (see online appendix).

We also graphically analysed changes in mastectomy rates after Jolie's editorial to assess whether any additional BRCA gene testing led to subsequent preventive mastectomies.[@ref7] As our data did not contain modifier codes that would indicate whether a mastectomy was preventive, we calculated monthly mastectomy rates in the overall study population as well as rates in the 60, 90, and 180 days after the test among women who underwent BRCA testing in 2013. If women responded to Jolie's editorial with more intensive treatment choices, we would expect rates of mastectomies to increase in the months after publication of the editorial. We included 90 and 180 day follow-up periods to allow sufficient time for women testing positive for BRCA to undergo mastectomy.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for the design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results
=======

Study population
----------------

Our sample included 9 532 836 women, of whom 2 546 635 (27%) were aged 46-55 and 2 018 218 (21%) were aged 56-64 in 2012 (table 1[](#tbl1){ref-type="table"}). Additionally, 3 118 836 (33%) women resided in the South, and 5 555 048 (58%) were in PPO plans. During the study period, 32 945 (0.35%) women had a BRCA test. Women who had BRCA tests were somewhat older (BRCA tested, 36% of women aged 46-55 and 22% aged 56-64; non-tested, 27% of women aged 46-55 and 21% aged 56-64), more heavily represented in the West (24% *v* 22%), and more likely to be covered by a PPO health plan (67% *v* 58%). Of 32 945 women who had a BRCA test during 2012-13, almost half (15 233) had the test in the 231 remaining days of the year after the Jolie editorial was published (14 May 2013), which represented less than a third of the two year study period. Characteristics of women who had the test before publication of the editorial compared with those who had the test after it are shown in appendix 1. Women were similar in most characteristics, except that those who had the test after the editorial were slightly more likely to be covered under a PPO plan (70% *v* 64%).

###### 

Study population. Values are numbers (percentages)

                                    Full sample (n=9 532 836)   Women who had BRCA testing (n=32 945)
  --------------------------------- --------------------------- ---------------------------------------
  **Age category, years**                                       
  18-25                             1 427 952 (15)              850 (3)
  26-35                             1 503 136 (16)              3674 (11)
  36-45                             2 036 895 (21)              9506 (29)
  46-55                             2 546 635 (27)              11 751 (36)
  56-64                             2 018 218 (21)              7164 (22)
  **US Census region**                                          
  Northeast                         2 157 935 (23)              7497 (23)
  North Central                     1 949 966 (20)              6370 (19)
  South                             3 118 836 (33)              10 464 (32)
  West                              2 100 345 (22)              7800 (24)
  Unknown                           205 754 (2)                 814 (2)
  **Insurance plan type**                                       
  Preferred provider organisation   5 555 048 (58)              22 049 (67)
  Health maintenance organisation   1 179 703 (12)              4151 (13)
  Consumer directed health plan     440 786 (5)                 1870 (6)
  Other                             2 033 167 (21)              3496 (11)

Rates of BRCA testing
---------------------

Daily BRCA test rates increased immediately and sharply after publication of the editorial. Rates rose from 0.71 tests per 100 000 women in the 15 business days before to 1.13 tests in the 15 business days after 14 May 2013. In comparison, daily BRCA test rates were relatively similar in the same period in 2012 (0.58 per 100 000 women in the 15 business days before 14 May versus 0.55 tests per 100 000 in the 15 business days after) (fig 1[](#f1){ref-type="fig"}). This corresponds to an adjusted difference-in-difference absolute daily increase of 0.45 tests per 100 000 women or a 64% relative increase (P\<0.001). Using a 30 day window, we estimated a difference-in-difference relative increase in BRCA testing rates of 52% (appendix 2).

![**Fig 1** Daily BRCA test rates in 15 business days before and after 14 May 2013 Jolie editorial versus control period in 2012. BRCA tests were identified with Current Procedural Terminology codes 81211-81217. Figure shows three day moving average of testing rate. Rates in 2012 are shown as control to account for seasonal trends](dess034760.f1_default){#f1}

Increases in BRCA testing persisted to the end of our study period (fig 2[](#f2){ref-type="fig"}). Average monthly test rates increased from 15.6 tests per 100 000 women in months January to April 2013 to 21.3 tests per 100 000 women during May to December 2013, a relative monthly increase of 37%. Nationally, our results imply 4500 additional BRCA tests and more than \$13.5m (£10.8m; €12.8) in incremental expenditures on BRCA tests in the 15 business days after the editorial among commercially insured women aged 18-64 (appendix 3).

![**Fig 2** Monthly BRCA test rates before and after May 2013 Jolie editorial, adjusted for days in month. Rates for 2012 are not shown because coding changes implemented in early 2012 limit ability to accurately identify rates of testing in first three months of 2012](dess034760.f2_default){#f2}

We saw no increase in mastectomy rates in the overall population, with an average of seven mastectomies a month per 100 000 women during January to April as well as during May to December 2013 (fig 3[](#f3){ref-type="fig"}). Moreover, among women who had BRCA tests, 60 day monthly mastectomy rates decreased from on average 10% during January to April 2013 to 7% during May to December 2013 (fig 4[](#f4){ref-type="fig"}), further suggesting that incremental BRCA tests obtained as a result of the Jolie editorial did not yield additional BRCA positive mutations that might warrant preventive mastectomy. Ninety and 180 day monthly mastectomy rates (post-BRCA testing) suggested a similar pattern.

![**Fig 3** Monthly mastectomy rates before and after May 2013 Jolie editorial versus control period in 2012, adjusted for length of month. Rates for 2012 are shown to serve as control to account for seasonal trends](dess034760.f3_default){#f3}

![**Fig 4** 60, 90, and 180 day monthly mastectomy rates among women who had BRCA test before and after May 2013 Jolie editorial. For each data point, denominator is number of women who had BRCA gene test during month and numerator is number of women who had mastectomy in 60 (or 90 or 180) days after BRCA gene test. Rates for 2012 are not shown because coding changes implemented in early 2012 limit ability to accurately identify rates of BRCA gene testing in first three months of 2012](dess034760.f4_default){#f4}

Discussion
==========

We observed a large and immediate increase in BRCA testing among commercially insured women aged 18-64 years in the United States after Angelina Jolie's editorial. Our findings illustrate that well delivered announcements by high profile figures may be a low cost and effective means to influencing healthcare decision making, particularly in this social media age.

However, both stable overall mastectomy rates and decreased mastectomy rates among women who had a BRCA test after the editorial suggest that additional BRCA testing induced by the editorial probably did not identify new BRCA mutations requiring preventive mastectomy. This may suggest that incremental tests performed had a lower pre-test probability of being positive than tests done before the editorial or that additional women identified as having a BRCA mutation after the editorial were less likely to undergo preventive mastectomy. This also suggests that celebrity announcements can reach a broad audience but may not effectively target the population that would benefit most from the test, in this case women with a family history of breast, ovarian, fallopian tube, or peritoneal cancer, as advised by the US Preventive Services Task Force.[@ref8]

Limitations of study
--------------------

Because we did not observe test results, we did not measure benefits associated with knowing one's BRCA status such as peace of mind or increased vigilance after learning one's risk factors. Moreover, as our data did not allow us to identify preventive mastectomies, preventive mastectomies among women who tested positive for the BRCA mutation may have increased after Jolie's editorial even though overall mastectomy rates remained steady. Moreover, rates of mastectomy among women who tested positive for the BRCA mutation could have increased after the time captured by our study period.[@ref9] [@ref10] Finally, although our study population was more general than that of previous studies, certain populations such as Medicare enrolees were not represented.

Conclusions
-----------

We found an immediate increase in BRCA testing rates after Angelina Jolie's breast cancer editorial in the *New York Times* but no change in overall mastectomy rates and a decrease in mastectomy rates among women who had the BRCA test. Celebrity announcements in the social media age can raise awareness and use of preventive care by a large and broad audience, although their ability to target subpopulations of interest may be limited.

### What is already known on this topic

1.  Celebrity endorsements for health related matters such as preventive screening, fad diets, and supplements are ubiquitous

2.  Evidence on whether celebrity endorsements actually affect health related behaviours remains limited

### What this study adds

1.  This study analysed the effect of an editorial on BRCA gene testing by Angelina Jolie on rates of BRCA testing and mastectomy in a large US population

2.  A 64% increase in BRCA testing rates occurred in the 15 business days after the editorial was published, but with no increase in mastectomy rates in the following months

3.  Celebrity announcements can influence use of healthcare services, but they may not effectively target the subpopulation at greatest risk for the underlying condition
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Click here for additional data file.
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